絞り込み

16533

広告

The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives.

著者 Schubert-Bast S , Rosenow F , Klein KM , Reif PS , Kieslich M , Strzelczyk A
Epilepsy Behav.2018 Jun 22 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (16view , 0users)

Full Text Sources

Miscellaneous

Tuberous sclerosis complex (TSC) is one of the most common genetic causes of epilepsy. Mutations in the TSC1 or TSC2 genes lead to the dysregulation of the mechanistic target of rapamycin (mTOR) pathway. This mTOR pathway hyperactivation is associated with several processes resulting in epileptic conditions. The occurrence of seizures and their treatment outcomes seem to play a crucial role in cognitive and behavioral developments in patients with TSC. Mechanistic target of rapamycin inhibitors have been proven to be effective in epilepsy treatment in individuals with TSC. Specifically, because of their disease-modifying mechanism of action, they have the capability to prevent epileptogenesis in patients with TSC. This article will provide an overview of the current evidence of and delineate future perspectives for mTOR inhibitors and their role in preventing epileptogenesis.
PMID: 29941212 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード